>
Switch to:

Opiant Pharmaceuticals Piotroski F-Score

: 2 (As of Today)
View and export this data going back to 2007. Start your Free Trial

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Opiant Pharmaceuticals has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Opiant Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

NAS:OPNT' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 8
Current: 2

2
8

During the past 13 years, the highest Piotroski F-Score of Opiant Pharmaceuticals was 8. The lowest was 2. And the median was 4.


Opiant Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Opiant Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Dec18 Dec19 Dec20
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 3.00 4.00 2.00

Opiant Pharmaceuticals Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 2.00 3.00 2.00

Competitive Comparison

For the Biotechnology subindustry, Opiant Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Opiant Pharmaceuticals Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun21) TTM:Last Year (Jun20) TTM:
Net Income was 0.725 + -0.686 + -2.844 + 1.684 = $-1.12 Mil.
Cash Flow from Operations was 0.422 + -1.634 + 1.712 + -2.076 = $-1.58 Mil.
Revenue was 9.106 + 9.924 + 6.387 + 11.259 = $36.68 Mil.
Gross Profit was 7.154 + 8.016 + 5.407 + 9.153 = $29.73 Mil.
Average Total Assets from the begining of this year (Jun20)
to the end of this year (Jun21) was
(39.437 + 42.242 + 60.613 + 58.903 + 61.758) / 5 = $52.5906 Mil.
Total Assets at the begining of this year (Jun20) was $39.44 Mil.
Long-Term Debt & Capital Lease Obligation was $19.62 Mil.
Total Current Assets was $60.52 Mil.
Total Current Liabilities was $5.78 Mil.
Net Income was 10.683 + 1.068 + -1.685 + -0.216 = $9.85 Mil.

Revenue was 20.641 + 7.67 + 4.283 + 6.313 = $38.91 Mil.
Gross Profit was 15.79 + 6.048 + 3.349 + 4.91 = $30.10 Mil.
Average Total Assets from the begining of last year (Jun19)
to the end of last year (Jun20) was
(28.825 + 41.368 + 40.281 + 38.267 + 39.437) / 5 = $37.6356 Mil.
Total Assets at the begining of last year (Jun19) was $28.83 Mil.
Long-Term Debt & Capital Lease Obligation was $0.04 Mil.
Total Current Assets was $38.68 Mil.
Total Current Liabilities was $5.11 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Opiant Pharmaceuticals's current Net Income (TTM) was -1.12. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Opiant Pharmaceuticals's current Cash Flow from Operations (TTM) was -1.58. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun20)
=-1.121/39.437
=-0.02842508

ROA (Last Year)=Net Income/Total Assets (Jun19)
=9.85/28.825
=0.34171726

Opiant Pharmaceuticals's return on assets of this year was -0.02842508. Opiant Pharmaceuticals's return on assets of last year was 0.34171726. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Opiant Pharmaceuticals's current Net Income (TTM) was -1.12. Opiant Pharmaceuticals's current Cash Flow from Operations (TTM) was -1.58. ==> -1.58 <= -1.12 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun20 to Jun21
=19.618/52.5906
=0.37303244

Gearing (Last Year: Jun20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun19 to Jun20
=0.035/37.6356
=0.00092997

Opiant Pharmaceuticals's gearing of this year was 0.37303244. Opiant Pharmaceuticals's gearing of last year was 0.00092997. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun21)=Total Current Assets/Total Current Liabilities
=60.518/5.784
=10.46300138

Current Ratio (Last Year: Jun20)=Total Current Assets/Total Current Liabilities
=38.682/5.106
=7.57579318

Opiant Pharmaceuticals's current ratio of this year was 10.46300138. Opiant Pharmaceuticals's current ratio of last year was 7.57579318. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Opiant Pharmaceuticals's number of shares in issue this year was 5.428. Opiant Pharmaceuticals's number of shares in issue last year was 4.258. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=29.73/36.676
=0.81061184

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=30.097/38.907
=0.7735626

Opiant Pharmaceuticals's gross margin of this year was 0.81061184. Opiant Pharmaceuticals's gross margin of last year was 0.7735626. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun20)
=36.676/39.437
=0.9299896

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun19)
=38.907/28.825
=1.34976583

Opiant Pharmaceuticals's asset turnover of this year was 0.9299896. Opiant Pharmaceuticals's asset turnover of last year was 1.34976583. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+0+1+0+1+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Opiant Pharmaceuticals has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Opiant Pharmaceuticals  (NAS:OPNT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Opiant Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Opiant Pharmaceuticals Business Description

Opiant Pharmaceuticals logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
233 Wilshire Blvd, Suite 280, Santa Monica, CA, USA, 90401
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.
Executives
Thomas Thomas T. director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Sinclair Michael director, 10 percent owner 86 GLOUCESTER PLACE LONDON XX W1U6HP
Collard Craig A director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Daly Richard J director 355 ALHAMBRA CIRCLE SUITE 1500 CORAL GABLES FL 33134
Macdougall Ann L. director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Silver Gabrielle Alison director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Gorman Brian other: General Counsel 233 WILSHIRE BLVD SUITE 280 SANTA MONICA CA 90401
Skolnick Phil officer: Chief Scientific Officer C/O DOV PHARMACEUTICAL, INC. 433 HACKENSACK AVENUE HACKENSACK NJ 07601
Crystal Roger director, 10 percent owner, officer: Chief Executive Officer 445 PARK AVE 10TH FL. NEW YORK NY 10022
Ellison Mark Jason Heath other: UK Managing Director C/O OPIANT PHARMACEUTICALS, INC. 201 SANTA MONICA BLVD., SUITE 500 SANTA MONICA CA 90401
Thompson Rahsaan other: General Counsel 233 WILSHIRE BOULEVARD SUITE 280 SANTA MONICA CA 90401
Mottiwala Aziz officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD SUITE 280 SANTA MONICA CA 90401
Wolf Geoffrey 10 percent owner 445 PARK AVENUE 10TH FL. NEW YORK NY 10022
Pollack Kevin director, officer: See Remarks 150 RAINVILLE ROAD TARPON SPRINGS FL 34689
Meuse Joseph J director, 10 percent owner 211 FALMOUTH STREET WARRENTON VA 20186

Opiant Pharmaceuticals Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)